Filing Details
- Accession Number:
- 0001209191-21-041038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-16 18:05:49
- Reporting Period:
- 2021-06-15
- Accepted Time:
- 2021-06-16 18:05:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1817713 | Janux Therapeutics Inc. | JANX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1376355 | Jay Lichter | C/O Janux Therapeutics, Inc. 11099 N. Torrey Pines Road, Suite 290 La Jolla CA 92037 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-15 | 1,138,665 | $0.00 | 1,330,815 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-06-15 | 2,382,191 | $0.00 | 3,713,006 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-06-15 | 674,211 | $0.00 | 4,387,217 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-06-15 | 2,696,843 | $0.00 | 2,696,843 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-06-15 | 1,153,238 | $0.00 | 3,850,081 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-06-15 | 629,411 | $17.00 | 4,479,492 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series Seed Convertible Preferred Stock | Disposition | 2021-06-15 | 888,888 | $0.00 | 1,138,665 | $0.00 |
Common Stock | Series Seed 2 Convertible Preferred Stock | Disposition | 2021-06-15 | 1,859,634 | $0.00 | 2,382,191 | $0.00 |
Common Stock | Series A Convertible Preferred Stock | Disposition | 2021-06-15 | 526,316 | $0.00 | 674,211 | $0.00 |
Common Stock | Series A Convertible Preferred Stock | Disposition | 2021-06-15 | 2,105,264 | $0.00 | 2,696,843 | $0.00 |
Common Stock | Series B Convertible Preferred Stock | Disposition | 2021-06-15 | 900,264 | $0.00 | 1,153,238 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.
- The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter shares voting and investment power with respect to the shares held by ABV SPV. Dr. Lichter disclaims beneficial ownership of all shares held by ABV SPV except to the extent of his actual pecuniary interest therein, if any.
- The shares were purchased in the Issuer's initial public offering.